Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimasertib - Day One Biopharmaceuticals

Drug Profile

Pimasertib - Day One Biopharmaceuticals

Alternative Names: AS-703026; EMD-1036239; MSC 1936369; MSC 1936369B; MSC1936369A

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santhera Pharmaceuticals
  • Developer Day One Biopharmaceuticals; Merck Serono; Sanofi
  • Class Amides; Aminopyridines; Antineoplastics; Iodobenzenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Discontinued Colorectal cancer; Haematological malignancies; Malignant melanoma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 17 Jan 2024 Australian & New Zealand Children's Haematology/Oncology Group plans a phase I/II trial for the treatment of Cancer (In children, In adults, Second-line or greater therapy) in Australia and Canada (PO) in March 2024 (NCT06208657)
  • 08 Feb 2022 Day One Biopharmaceuticals has patents pending for pimasertib in combination with tovorafenib for treating cancer in US
  • 17 Sep 2021 Phase-I clinical trials in Solid tumours in USA (PO) (Day One Biopharmaceuticals pipeline, September 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top